KURA Kura Oncology Inc

$KURA - I think accumulation will start in KURA over next few weeks. It is one of the least risk stock with huge potential, good management team (With CEO Troy buying 200k shares at around $ 12 in last 2 months). But this is for longer term hold. Very

$KURA analyst target $30 yet $BMEA at at $1:30. Something not not sit right at all here, so I am very bullish on BMEA

$KURA do they know what I know? • H.C. Wainwright — $40 (Buy) • Wedbush — $38 (Outperform; raised from $36 in mid-Aug) • BofA — ~$30–$31 (Buy) • Barclays — $28 (Buy) • Mizuho — $25 (Buy) • Citizens / JMP, Raymond James, others — $24 • Lake Street — $23 (Buy)

$KURA - looks like below CNBC Pro article (just posted < 1 hour ago) is about KURA based on JPM initiation with $30 PT. And that is why SP started flying quickly. https://www.cnbc.com/2026/10/01/this-biotech-making-precision-medicines-for-cancer-could-nearly-triple-says-jpmorgan.html Very Very

$KURA read outs coming soon. The next $RVMD and my followers know what happened there. From $40 to $224. 6x

$KURA KURA, today announced comprehensive preclinical data supporting KO-7246 as a potential best-in-class menin inhibitor for diabetes. KO-7246 regenerated functional β-cell mass, demonstrated durable glycemic control, and increased endogenous insulin production in preclinical models of Type 1 and Type 2 diabetes. In human islets, KO-7246 selectively increased β-cell proliferation and improved glucose-responsive insulin secretion. Together, the findings establish a differentiated preclinical profile including validated activity as a menin inhibitor, durable disease-relevant activity, and confirmed translation to a human-islet setting.

$KURA Preclinical data for Kura Oncology's new menin inhibitor, KO-7246, will be presented at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting on September 29, 2026. Presentation Details Title: Next-generation menin inhibitor KO-7246 regenerates beta cell mass in diabetic rodent and human islet models Presenter: Francis Burrows, Ph.D., Chief Scientific Officer Session: OP 05 From Islet Failure to Regeneration: New Strategies in Type 2 Diabetes Date and Time: September 29, 2026, 11:15–11:30 a.m. CEST

$KURA 14.82 million shares sold short. 18% of float 9 days to cover. Kura reps have been visiting hematologists the rise of komzifti is upon us.

$KURA for those asking their drug includes cancer, heart disease and diabetes. Could be massive

UBS reiterated $KURA Buy-$15 and said -- KURA's 2Q26 metrics reinforced strong early Komzifti launch execution, with accelerating new patient starts, growing repeat prescribing, and favorable access dynamics supporting continued uptake. $SNDX $BMY AMGN ABBV - RHHBY UBS added — Management increasingly emphasized Komzifti's potential as a frontline AML backbone therapy, citing high current combination use (~40%), upcoming FLT3 combination data, encouraging frontline efficacy, and the prospect for multi-year treatment duration. Despite growing competition, mgmt remains confident that Komzifti's tolerability, combination flexibility, and clean long-term safety profile will become increasingly important differentiators as menin inhibitors move earlier in treatment. Separately, darlifarnib continues to emerge as a promising combination platform across targeted therapies, with additional data expected in 2027 helping further validate the strategy.

$KURA Kura Oncology initiated with an Overweight at JPMorgan JPMorgan initiated coverage of Kura Oncology with an Overweight rating and $30 price target. The firm believes Komzifti provides a "floor" for the shares with potential upside from darlifarnib. JPMorgan is positive on Kura's transition into a commercial-stage oncology company with Komzifti in relapsed/refractory NPM1-mutant acute myeloid leukemia. A clean label with no ziftomenib-related Qblack-box warning "is a clear differentiator among the menin class," the analyst tells investors in a research note. The firm sees total sales of $1.5B and says darlifarnib, a next-generation farnesyl transferase inhibitor, broadens Kura beyond a single menin inhibitor launch by potentially expanding into solid-tumor combinations.

$KURA Held very strong today above 11.69. You won't be able to buy shares under 12 for much longer.

$KURA dipped under 11. Fair play. Might as well give us some shares under 10 before the rebound.

$KURA ok. Found it. Down 20% since insider open market BIG BOY buy. Hmmmmm. Going to start a position, average in until solid reversal.

$KURA This upgrade is dumb. That drug that the analist mentioned is so early and one question how did she get the job. 90% of drugs fail in trials and kura do not have money for trials. Wilson said we need funds for this and we just do not have the funds. I bet JP Morgan is doing an underwriting in Kura soon LOL

$KURA Management to host webcast and conference call on October 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT

$KURA I thought conference call would be today. Why hold conference call 2 weeks after PR? Management to host webcast and conference call on October 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT –

$KURA insiders are selling shares for the last several days. and a lot of shares, looks like pretrial drugs are just to let them to dump this crap

$KURA $KOD damn u actually admitted u for kura wrong but refuse to admit $ABVX WRONG $INBX Wrong $MLYS WRONG TRVI wrong and this just in last monthish! 😂🤣, dude, not a single spec bio right, bruh.....😆🙄

$KURA Chart pattern and Technical analysis time! (YAY!) We have a megaphone chart pattern that generally gives zero fucks about the MA's except for earlier this year in May when it showed the 50 some respect. Only hope at this point is an oversold stochastic + 50MA could get this stock accumulating again, but who really knows? Yeah, we're also at the 50% Fib, but that doesn't prove the stock is going to turn around. Let's see what happens tomorrow, but if I had to make a prediction, we have a 1-3 day rebound and then continue further down the rabbit hole toward 10.